S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:TNGX

Tango Therapeutics (TNGX) Stock Price, News & Analysis

$7.31
-0.06 (-0.81%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$6.93
$7.36
50-Day Range
$7.31
$12.39
52-Week Range
$2.47
$13.03
Volume
526,400 shs
Average Volume
658,255 shs
Market Capitalization
$780.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

Tango Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
136.0% Upside
$17.25 Price Target
Short Interest
Bearish
19.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.14mentions of Tango Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$2.10 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.44 out of 5 stars

Medical Sector

690th out of 907 stocks

Pharmaceutical Preparations Industry

317th out of 423 stocks

TNGX stock logo

About Tango Therapeutics Stock (NASDAQ:TNGX)

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

TNGX Stock Price History

TNGX Stock News Headlines

Tango Therapeutics (NASDAQ:TNGX) Trading Down 3.8%
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
Recap: Tango Therapeutics Q4 Earnings
TNGX Aug 2024 20.000 put
TNGX Mar 2024 7.500 call
TNGX Mar 2024 12.500 call
Tango Therapeutics initiated with a Buy at B. Riley
See More Headlines
Receive TNGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/18/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TNGX
Fax
N/A
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.25
High Stock Price Target
$18.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+136.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-101,740,000.00
Net Margins
-278.55%
Pretax Margin
-278.18%

Debt

Sales & Book Value

Annual Sales
$36.53 million
Book Value
$2.48 per share

Miscellaneous

Free Float
100,117,000
Market Cap
$780.27 million
Optionable
Optionable
Beta
0.83
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Barbara L. Weber M.D. (Age 66)
    President, CEO & Director
    Comp: $941.16k
  • Ms. Daniella Beckman CPA (Age 45)
    Chief Financial Officer
    Comp: $619.13k
  • Dr. Alan Ashworth FRS (Age 62)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Dr. Levi Garraway M.D. (Age 55)
    Ph.D., Founder
  • Dr. William G. Kaelin Jr. (Age 66)
    M.D., Founder & Member of Scientific Advisory Board
  • Dr. Timothy K. Lu M.D. (Age 43)
    Ph.D., Founder
  • Dr. Antoni Ribas M.D. (Age 57)
    Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Jannik N. Andersen Ph.D.
    Chief Scientific Officer
  • Mr. Douglas J. Barry Esq. (Age 53)
    J.D., Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
  • Mr. John C. Ross M.S.
    Vice President of Human Resources

TNGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Tango Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tango Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNGX shares.
View TNGX analyst ratings
or view top-rated stocks.

What is Tango Therapeutics' stock price target for 2024?

5 brokers have issued 12 month target prices for Tango Therapeutics' stock. Their TNGX share price targets range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.25 in the next year. This suggests a possible upside of 136.0% from the stock's current price.
View analysts price targets for TNGX
or view top-rated stocks among Wall Street analysts.

How have TNGX shares performed in 2024?

Tango Therapeutics' stock was trading at $9.90 at the beginning of the year. Since then, TNGX stock has decreased by 26.2% and is now trading at $7.31.
View the best growth stocks for 2024 here
.

When is Tango Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our TNGX earnings forecast
.

How were Tango Therapeutics' earnings last quarter?

Tango Therapeutics, Inc. (NASDAQ:TNGX) released its earnings results on Monday, March, 18th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.04. The firm earned $5.43 million during the quarter, compared to analyst estimates of $7.86 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 41.96% and a negative net margin of 278.55%.

Who are Tango Therapeutics' major shareholders?

Tango Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Mass General Brigham Inc (0.33%). Insiders that own company stock include Adam Crystal, Barbara Weber, Boxer Capital, Llc, Daniella Beckman, Douglas Barry and Rock Ventures Iv LP Third.
View institutional ownership trends
.

How do I buy shares of Tango Therapeutics?

Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TNGX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners